Equity
Investments - Gross Unrealized Losses
Neurocrine Biosciences Investments - Gross Unrealized Losses increased by 371.5% to $1.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 398.0%, from $317.30M to $1.58B.
Analysis
StatementBalance Sheet Statement
SectionEquity
First reportedQ2 2021
Last reportedQ1 2026May 5, 2026
Metric ID:
investments_gross_unrealized_lossesHistorical Data
7 periods
| Q2 '21 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $245.50M | $458.70M | $317.30M | $401.80M | $349.80M | $335.10M | $1.58B |
| QoQ Change | — | +86.8% | -30.8% | +26.6% | -12.9% | -4.2% | +371.5% |
| YoY Change | — | — | — | — | — | -26.9% | +398.0% |
Range$245.50M – $1.58B
CAGR+246.0%
Avg YoY Growth+185.5%
Median YoY Growth+185.5%
Investments - Gross Unrealized Losses at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's investments - gross unrealized losses?
- Neurocrine Biosciences (NBIX) reported investments - gross unrealized losses of $1.58B in Q1 2026.
- How has Neurocrine Biosciences's investments - gross unrealized losses changed year-over-year?
- Neurocrine Biosciences's investments - gross unrealized losses increased by 398.0% year-over-year, from $317.30M to $1.58B.